Sialyltransferase ST3GAL6 as a marker for multiple myeloma
AssigneeNational University of Ireland, Galway
InventorsSiobhan Glavey, Lokesh Joshi, Michael O'Dwyer
Life of this patent
Estimating the term…
Abstract
The present invention relates to the sialyltransferase ST3GAL6 for use as a biomarker for multiple myeloma, and especially as a marker for myelomas with inferior survival rates. The inventors have shown that glycosylation gene expression is dysregulated in Multiple Myeloma and that overexpression of the sialyltransferase ST3GAL6 is associated with inferior survival rates in patients.
Claims2
A method of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject a modulator of ST3GAL6 in an amount sufficient to decrease ST3GAL6 expression or activity, wherein the modulator of ST3GAL6 is an interfering RNA specific for ST3GAL6.
Dependencies are inferred from the claim text.